Ledger.Open graph →
SEC Form D · filed September 28, 2015

Akari Therapeutics Plc

Offering
$75.0M
Sold
$75.0M
Exemption
Rule 506(b)
Industry
Biotechnology
Location
London, United Kingdom
Type
—

Rule 506(b): private placement to accredited investors, no public advertising.

People & firms on this filing (16)

Stuart Ungar · London, United KingdomDirectorGur Roshwalb · London, United KingdomExec · DirectorClive Richardson · London, United KingdomExec · DirectorRay Prudo · London, United KingdomDirectorMark Cohen · Washington, Washington, D.C.DirectorAllan Shaw · London, United KingdomDirectorJames Hill · North Vancouver, British Columbia, CanadaDirectorDov Elefant · New York, NYExecStuart Ungar · London, United KingdomDirectorGur Roshwalb · London, United KingdomExec · DirectorMark Cohen · London, United KingdomDirectorClive Richardson · London, United KingdomExec · DirectorAllan Shaw · London, United KingdomDirectorJames Hill · London, United KingdomDirectorRay Prudo · London, United KingdomDirectorDov Elefant · London, United KingdomExec

Public SEC Form D (Reg D) filing. · View issuer on SEC EDGAR ↗